MSLN and glioblastoma: Three out of five cell lines from patients with GBM exhibited positive specific staining for mesothelin,; co-staining with a glia cell -specific marker exhibited co-staining of anti-mesothelin - reactive cells thus enabling us to conclude that mature mesothelin is a viable biomarker for human GBM tumors (Supplementary Figure 2).